{"success":true,"data":{"pressRelease":{"id":"19764","rtpr_id":"nGNX9ptnM","ticker":"BIOA","exchange":"NASDAQ","all_tickers":["BIOA"],"title":"BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026","author":"Globe Newswire","published_at":"2026-05-04T20:30:00.196Z","article_body":"Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET\n\nEvent will feature Phase 1 clinical data for BGE-102 and the therapeutic\nrationale for development in atherosclerotic cardiovascular disease (ASCVD)\nand retinal disease\n\nFour leading academic and clinical experts will join BioAge management for\npresentations, followed by a live question-and-answer session\n\nEMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(Nasdaq: BIOA) (\"BioAge\"), a clinical-stage biopharmaceutical company\ndeveloping therapeutic product candidates for cardiometabolic diseases by\ntargeting the biology of human aging, today announced that it will host an R&D\nDay webcast on Friday, May 8, 2026, from 12:30 to 2 PM Eastern Time.\n\nThe event will focus on BGE-102, the Company's potent, structurally novel,\norally available NLRP3 inflammasome inhibitor with potential best-in-class\nattributes. Members of BioAge's leadership team will present Phase 1 clinical\ndata and the therapeutic rationale for advancing BGE-102 in atherosclerotic\ncardiovascular disease (ASCVD) and retinal disease, two indication areas in\nwhich NLRP3-driven inflammation is implicated in disease pathology.\n\nBioAge management will be joined by four leading academic and clinical\nexperts, who will share their perspectives on NLRP3 biology and the diseases\nBGE-102 is being developed to treat:\n* Michael Davidson, MD — Professor and Director of the Lipid Clinic at the\nUniversity of Chicago Pritzker School of Medicine, Chief Executive Officer of\nNewAmsterdam Pharma, and a member of BioAge's Board of Directors — will\ndiscuss the role of inflammation in ASCVD and emerging therapeutic approaches\nto cardiovascular risk.\n* Brian Hafler, MD, PhD — Associate Professor of Ophthalmology & Visual\nScience at Yale School of Medicine — will discuss NLRP3-mediated\ninflammation in retinal disease.\n* David Boyer, MD — Senior Partner at Retina-Vitreous Associates Medical\nGroup — will discuss unmet clinical need in diabetic macular edema and\ngeographic atrophy, and the opportunity for an oral anti-inflammatory therapy.\n* Matthias Geyer, PhD — Professor of Structural Immunology and Scientific\nDirector of the Institute of Structural Biology at the University of Bonn —\nwill discuss the structural biology of NLRP3 inhibition and the molecular\nbasis for BGE-102's differentiated mechanism.\nThe presentations will be followed by a live question-and-answer session.\n\nWebcast Information\n\nTo view a live webcast of the event, register here\n(https://www.globenewswire.com/Tracker?data=Ryr_CE2yuPuIs1kPCgX21bzHosu02hFEbHZSlwV2zYlF6VHjhum7wRTzHUCc0EXbYtL2P5BWM2G4VF2T4UjVR9EWToe9mdEqggSy6mMyespZaconQRCaItNQVaI4dDXjoWbTMCjq1IV8aPDc66Y2Ag==).\nA recording of the webcast will be available in the \"Events\" section of\nBioAge's investor relations website at https://ir.bioagelabs.com/.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company's lead product candidate, BGE-102, is a potent,\norally available, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for cardiovascular risk and retinal diseases including diabetic\nmacular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a\nwell-tolerated profile and potential best-in-class reductions in hsCRP and\nother inflammatory biomarkers in participants with obesity and elevated\ninflammation. Phase 2 cardiovascular risk proof-of-concept data are\nanticipated in H2 2026, and Phase 1b/2a diabetic macular edema\nproof-of-concept data are anticipated in mid-2027. The Company is also\ndeveloping long-acting injectable and oral small molecule APJ agonists for\nobesity. BioAge’s additional preclinical programs, which leverage insights\nfrom the Company’s proprietary discovery platform built on human longevity\ndata, address key pathways involved in metabolic aging.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9ptnM","title":"BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026","author":"Globe Newswire","ticker":"BIOA","created":"2026-05-04T20:30:00.196Z","tickers":["BIOA"],"exchange":"NASDAQ","article_body":"Live webcast on Friday, May 8, 2026, beginning at 12:30 PM ET\n\nEvent will feature Phase 1 clinical data for BGE-102 and the therapeutic\nrationale for development in atherosclerotic cardiovascular disease (ASCVD)\nand retinal disease\n\nFour leading academic and clinical experts will join BioAge management for\npresentations, followed by a live question-and-answer session\n\nEMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(Nasdaq: BIOA) (\"BioAge\"), a clinical-stage biopharmaceutical company\ndeveloping therapeutic product candidates for cardiometabolic diseases by\ntargeting the biology of human aging, today announced that it will host an R&D\nDay webcast on Friday, May 8, 2026, from 12:30 to 2 PM Eastern Time.\n\nThe event will focus on BGE-102, the Company's potent, structurally novel,\norally available NLRP3 inflammasome inhibitor with potential best-in-class\nattributes. Members of BioAge's leadership team will present Phase 1 clinical\ndata and the therapeutic rationale for advancing BGE-102 in atherosclerotic\ncardiovascular disease (ASCVD) and retinal disease, two indication areas in\nwhich NLRP3-driven inflammation is implicated in disease pathology.\n\nBioAge management will be joined by four leading academic and clinical\nexperts, who will share their perspectives on NLRP3 biology and the diseases\nBGE-102 is being developed to treat:\n* Michael Davidson, MD — Professor and Director of the Lipid Clinic at the\nUniversity of Chicago Pritzker School of Medicine, Chief Executive Officer of\nNewAmsterdam Pharma, and a member of BioAge's Board of Directors — will\ndiscuss the role of inflammation in ASCVD and emerging therapeutic approaches\nto cardiovascular risk.\n* Brian Hafler, MD, PhD — Associate Professor of Ophthalmology & Visual\nScience at Yale School of Medicine — will discuss NLRP3-mediated\ninflammation in retinal disease.\n* David Boyer, MD — Senior Partner at Retina-Vitreous Associates Medical\nGroup — will discuss unmet clinical need in diabetic macular edema and\ngeographic atrophy, and the opportunity for an oral anti-inflammatory therapy.\n* Matthias Geyer, PhD — Professor of Structural Immunology and Scientific\nDirector of the Institute of Structural Biology at the University of Bonn —\nwill discuss the structural biology of NLRP3 inhibition and the molecular\nbasis for BGE-102's differentiated mechanism.\nThe presentations will be followed by a live question-and-answer session.\n\nWebcast Information\n\nTo view a live webcast of the event, register here\n(https://www.globenewswire.com/Tracker?data=Ryr_CE2yuPuIs1kPCgX21bzHosu02hFEbHZSlwV2zYlF6VHjhum7wRTzHUCc0EXbYtL2P5BWM2G4VF2T4UjVR9EWToe9mdEqggSy6mMyespZaconQRCaItNQVaI4dDXjoWbTMCjq1IV8aPDc66Y2Ag==).\nA recording of the webcast will be available in the \"Events\" section of\nBioAge's investor relations website at https://ir.bioagelabs.com/.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company's lead product candidate, BGE-102, is a potent,\norally available, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for cardiovascular risk and retinal diseases including diabetic\nmacular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a\nwell-tolerated profile and potential best-in-class reductions in hsCRP and\nother inflammatory biomarkers in participants with obesity and elevated\ninflammation. Phase 2 cardiovascular risk proof-of-concept data are\nanticipated in H2 2026, and Phase 1b/2a diabetic macular edema\nproof-of-concept data are anticipated in mid-2027. The Company is also\ndeveloping long-acting injectable and oral small molecule APJ agonists for\nobesity. BioAge’s additional preclinical programs, which leverage insights\nfrom the Company’s proprietary discovery platform built on human longevity\ndata, address key pathways involved in metabolic aging.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-04T20:30:00.2376203Z","server_sent_at_ms":1777926600237},"received_at":"2026-05-04T20:30:00.408Z","source_url":null},"analysis":{"id":"17323","press_release_id":"19764","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"BioAge will host an R&D Day on May 8, 2026, to present Phase 1 data for its lead NLRP3 inhibitor BGE-102, targeting cardiovascular and retinal diseases.\n\nThe event will feature presentations from four academic and clinical experts, including Board Member Dr. Michael Davidson, discussing the role of inflammation and the therapeutic rationale for BGE-102.\n\nThe company updated its development timeline, anticipating Phase 2 cardiovascular risk proof-of-concept data in H2 2026 and Phase 1b/2a diabetic macular edema data in mid-2027.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"R&D Day to spotlight BGE-102 Phase 1 data with Phase 2 catalysts defined for H2 2026."},"keyFigures":{"drugName":"BGE-102","phaseOfTrial":"Phase 1"},"quotedText":"The event will focus on BGE-102, the Company's potent, structurally novel, orally available NLRP3 inflammasome inhibitor with potential best-in-class attributes.","namedEntities":{"people":[{"name":"Michael Davidson","role":"Board Member, CEO of NewAmsterdam Pharma"},{"name":"Brian Hafler","role":"Associate Professor, Yale School of Medicine"},{"name":"David Boyer","role":"Senior Partner, Retina-Vitreous Associates Medical Group"},{"name":"Matthias Geyer","role":"Professor, University of Bonn"},{"name":"Chris Patil","role":"PR Contact"},{"name":"Dov Goldstein","role":"IR Contact"}],"products":["BGE-102"],"companies":[{"name":"BioAge Labs, Inc.","ticker":"BIOA"},{"name":"NewAmsterdam Pharma","relationship":"partner / Board Member affiliation"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Announcement of an R&D Day featuring Phase 1 data for lead asset BGE-102. The inclusion of four key opinion leaders and the specification of upcoming Phase 2 catalysts (H2 2026 and mid-2027) provide concrete visibility into the clinical development timeline."},"tickerRelevance":{"others":[],"primary":"BIOA"},"globalImportance":15,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"R&D Day / Data Presentation","catalystVisibility":"Phase 2 data anticipated H2 2026"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"BioAge will host an R&D Day on May 8, 2026, to present Phase 1 data for its lead NLRP3 inhibitor BGE-102, targeting cardiovascular and retinal diseases.\n\nThe event will feature presentations from four academic and clinical experts, including Board Member Dr. Michael Davidson, discussing the role of inflammation and the therapeutic rationale for BGE-102.\n\nThe company updated its development timeline, anticipating Phase 2 cardiovascular risk proof-of-concept data in H2 2026 and Phase 1b/2a diabetic macular edema data in mid-2027.","key_figures":{"drugName":"BGE-102","phaseOfTrial":"Phase 1"},"named_entities":{"people":[{"name":"Michael Davidson","role":"Board Member, CEO of NewAmsterdam Pharma"},{"name":"Brian Hafler","role":"Associate Professor, Yale School of Medicine"},{"name":"David Boyer","role":"Senior Partner, Retina-Vitreous Associates Medical Group"},{"name":"Matthias Geyer","role":"Professor, University of Bonn"},{"name":"Chris Patil","role":"PR Contact"},{"name":"Dov Goldstein","role":"IR Contact"}],"products":["BGE-102"],"companies":[{"name":"BioAge Labs, Inc.","ticker":"BIOA"},{"name":"NewAmsterdam Pharma","relationship":"partner / Board Member affiliation"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:6c7fa2f5e3b62e83","schema_hash":"sha256:ee8f711bc9bfba0d","created_at":"2026-05-06T16:49:10.572Z","global_importance":15,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"R&D Day / Data Presentation","catalystVisibility":"Phase 2 data anticipated H2 2026"}},"durationMs":null,"modelName":"glm-4.7"}}